Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(2):82-84; doi:10.1093/jnci/94.2.82
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 2, 82-84, January 16, 2002
© 2002 Oxford University Press

NEWS

Could Less be More? Low-Dose Chemotherapy Goes on Trial

Ken Garber

Judah Folkman, M.D., is accustomed to skeptics. When he first proposed, 30 years ago, the existence of a protein in the blood that blocked tumor blood vessel growth, the idea was almost universally ridiculed. Antiangiogenesis, of course, is now mainstream.

In April 2000, Folkman offered a new heresy: continuous, low-dose chemotherapy that, by targeting the endothelial cells that form the tumor’s blood supply, might work against drug-resistant tumors.

"We said that, in some patients, you may be able to rescue them by changing the schedule and doing antiangiogenic chemotherapy," said Folkman. The idea, also dubbed "low-dose" or "metronomic" chemotherapy, challenged the long-entrenched "more is better" orthodoxy, and many oncologists openly scoffed.

Now Folkman’s idea is being put to the test. Three North American clinical trials of metronomic chemotherapy are under way. Each . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
U. Emmenegger, S. Man, Y. Shaked, G. Francia, J. W. Wong, D. J. Hicklin, and R. S. Kerbel
A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens
Cancer Res., June 1, 2004; 64(11): 3994 - 4000.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. M. Groen, A. H. W. van der Leest, E. Fokkema, P. R. Timmer, G. D. Nossent, W. J. G. M. Smit, J. Nabers, H. J. Hoekstra, J. Hermans, R. Otter, et al.
Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study
Ann. Onc., March 1, 2004; 15(3): 427 - 432.
[Abstract] [Full Text] [PDF]